EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study

Roberta Scafetta, Raffaella Troiano, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Marco Donato, Simone Foderaro, Fabio Venuti, Francesco Antonio Vilardi, Valentina Ricozzi und 48 weitere

European Journal of Cancer · 2026-05 · 239 · 116703

DOI: 10.1016/j.ejca.2026.116703 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Roberta Scafetta und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma 00128, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Denosumab, Bone Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Preclinical evidence suggests that BRCA1/2-mutated tumors may rely on RANKL signaling for survival and proliferation. RANKL inhibition with denosumab could disrupt tumor-bone microenvironment crosstalk and potentially limit metastatic progression. We evaluated the association between denosumab and real-world progression-free survival (rwPFS) in germline BRCA1/2-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) with bone metastases. METHODS: We performed a retrospective, multicenter study across 24 Italian hospitals including HR+/HER2- bone mBC patients treated in first- or second-line with a CDK4/6 inhibitor plus endocrine therapy. rwPFS was estimated by Kaplan-Meier and compared with log-rank tests. Center-stratified multivariable Cox models adjusted for clinically relevant covariates were used to assess the association between denosumab exposure and rwPFS. Effect modification by BRCA status was evaluated using a denosumab×BRCA1/2 mutation status. RESULTS: Among 1399 patients, 46 harbored germline BRCA1/2 mutations (13 BRCA1, 33 BRCA2), and 21 of these patients received denosumab. Among patients not receiving denosumab, BRCA1/2-wild-type/unknown patients had better rwPFS than BRCA1/2-mutated patients (median 28 vs 13 months; hazard ratio (HR) 0.48, 95% CI 0.32-0.73; p = 0.001). Among BRCA1/2-wild-type/unknown patients, denosumab use did not affect rwPFS (HR 0.98, 95% CI 0.85-1.12). Conversely, denosumab use was associated with longer rwPFS among patients with BRCA1/2 mutations (median 35 months, 95% CI 24-NR vs 13 months, 95% CI 9-27; HR 0.34, 95% CI 0.16-0.74; p = 0.006), with no significant difference between BRCA1 and BRCA2-mutated subgroups. Multivariable analysis confirmed the rwPFS benefit of denosumab in BRCA1/2-mutated patients (adjusted HR 0.45, 95% CI 0.21-0.99; p = 0.048). CONCLUSION: In this real-world cohort, denosumab use was associated with longer rwPFS in germline BRCA1/2-mutated HR+/HER2- mBC with bone metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDenosumabBone NeoplasmsProtein Kinase InhibitorsBone Density Conservation AgentsHumansFemaleMiddle AgedRetrospective StudiesAgedProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesItalyBRCA1 ProteinBRCA2 ProteinAdultCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Germ-Line MutationReceptors, EstrogenReceptors, ProgesteroneMutation

Stichwörter der Autor:innen

BRCA1BRCA2Bone metastasesDenosumabHR+ /HER2 − breast cancerRANKLReal-world progression-free survival

Substanzen

DenosumabErb-b2 Receptor Tyrosine KinasesBRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6BRCA2 protein, humanProtein Kinase InhibitorsCDK4 protein, human

Autor:innen und Institutionen

  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma 00128, Italy.
  • Medical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, Viterbo 01100, Italy.
  • Division of Medical Oncology, "G.Martino" University Hospital, Via Consolare Valeria 1, Messina 98124, Italy.
  • Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, Roma 00128, Italy.
  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma 00128, Italy. Electronic address: m.iuliani@policlinicocampus.it.
  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma 00128, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo…

Zitieren

APA

Scafetta, R., Troiano, R., Gullotta, C., Guarino, A., Fiore, C., Sisca, L., Speziale, E., Donato, M., Foderaro, S., Venuti, F., Vilardi, F. A., Ricozzi, V., Iuliani, M., Simonetti, S., Cavaliere, S., Cortellini, A., Cesa, A., Botticelli, A., Scagnoli, S., …, & Fabbri, M. A. (2026). Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. European Journal of Cancer, 239, 116703. https://doi.org/10.1016/j.ejca.2026.116703

Vancouver

Scafetta R, Troiano R, Gullotta C, Guarino A, Fiore C, Sisca L, et al. Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. European Journal of Cancer. 2026;239:116703. doi:10.1016/j.ejca.2026.116703

BibTeX
@article{Scafetta2026,
  author = {Scafetta, Roberta and Troiano, Raffaella and Gullotta, Carla and Guarino, Alessandra and Fiore, Cristina and Sisca, Luisana and Speziale, Elena and Donato, Marco and Foderaro, Simone and Venuti, Fabio and Vilardi, Francesco Antonio and Ricozzi, Valentina and Iuliani, Michele and Simonetti, Sonia and Cavaliere, Silvia and Cortellini, Alessio and Cesa, Annalisa La and Botticelli, Andrea and Scagnoli, Simone and Pisegna, Simona and Criscitiello, Carmen and Pedersini, Rebecca and Sposetti, Caterina and Tiberi, Elisa and D'Auria, Giuliana and Vergati, Matteo and Mazzotta, Marco and Caputo, Roberta and Verrazzo, Annarita and Garrone, Ornella and Domati, Federica and Piombino, Claudia and Lisa, Francesca Sofia Di and Filomeno, Lorena and Arcuri, Teresa and Puce, Federica and Riva, Federica and Palleschi, Michela and Sirico, Marianna and Piras, Marta and Stucci, Luigia Stefania and Lisi, Delia De and Orsaria, Paolo and Grasso, Antonella and Ippolito, Edy and Ramella, Sara and Visani, Luca and Livi, Lorenzo and Gori, Stefania and Rossi, Luigi and Meattini, Icro and Tagliaferri, Barbara and Caffo, Orazio and Bonomo, Maria Vittoria and Portarena, Ilaria and Irelli, Azzurra and Cretella, Elisabetta and Porta, Camillo and Bianchini, Giampaolo and Fabbri, Maria Agnese},
  title = {Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {239},
  pages = {116703},
  doi = {10.1016/j.ejca.2026.116703}
}
Kostenlos starten →